Assessment of clinical and radiological findings for risk evaluation of secondary interstitial lung diseases associated with cancer treatments
Not Applicable
- Conditions
- Patients with cancer or suspected cancer who have interstitial lung lesions
- Registration Number
- JPRN-UMIN000052426
- Lead Sponsor
- Hamamatsu University School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 300
Inclusion Criteria
Not provided
Exclusion Criteria
Patients with any of the following will not be included in the study: 1. patients with no diagnosis or clinical suspicion of cancer 2. patients with no evidence of fibrosis on chest CT 3. patients who are not scheduled for treatment for cancer
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Cumulative incidence of lung injury: The cumulative incidence of lung injury is determined by the Gray test, from the date of enrollment to the occurrence of lung injury. Death from any cause is treated as a competing risk.
- Secondary Outcome Measures
Name Time Method Analysis of risk factors for lung injury: obtained by univariate and multivariate Fine-Gray tests. Analysis of risk factors for lung injury by cancer treatment